Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current and future therapies for type 1 diabetes.
von Scholten BJ, Kreiner FF, Gough SCL, von Herrath M. von Scholten BJ, et al. Among authors: von herrath m. Diabetologia. 2021 May;64(5):1037-1048. doi: 10.1007/s00125-021-05398-3. Epub 2021 Feb 17. Diabetologia. 2021. PMID: 33595677 Free PMC article. Review.
Current state of antigen-specific immunotherapy for type 1 diabetes.
Kreiner FF, von Scholten BJ, Coppieters K, von Herrath M. Kreiner FF, et al. Among authors: von scholten bj, von herrath m. Curr Opin Endocrinol Diabetes Obes. 2021 Aug 1;28(4):411-418. doi: 10.1097/MED.0000000000000647. Curr Opin Endocrinol Diabetes Obes. 2021. PMID: 34101651 Review.
Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes.
Yesildag B, Mir-Coll J, Neelakandhan A, Gibson CB, Perdue NR, Rufer C, Karsai M, Biernath A, Forschler F, Jin PW, Misun PM, Title A, Hierlemann A, Kreiner FF, Wesley JD, von Herrath MG. Yesildag B, et al. Among authors: von herrath mg. Clin Immunol. 2022 Nov;244:109118. doi: 10.1016/j.clim.2022.109118. Epub 2022 Sep 6. Clin Immunol. 2022. PMID: 36084852
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, Gumprecht J, Hansen TK, Mathieu C, Morales C, Mosenzon O, Segel S, Tsoukas G, Pieber TR; Anti-IL-21–liraglutide Study Group investigators and contributors. von Herrath M, et al. Lancet Diabetes Endocrinol. 2021 Apr;9(4):212-224. doi: 10.1016/S2213-8587(21)00019-X. Epub 2021 Mar 1. Lancet Diabetes Endocrinol. 2021. PMID: 33662334 Clinical Trial.
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Dejgaard TF, von Scholten BJ, Christiansen E, Kreiner FF, Bardtrum L, von Herrath M, Mathieu C, Madsbad S; ADJUNCT ONE and ADJUNCT TWO Investigators. Dejgaard TF, et al. Among authors: von scholten bj, von herrath m. Diabetes Obes Metab. 2021 Dec;23(12):2752-2762. doi: 10.1111/dom.14532. Epub 2021 Sep 28. Diabetes Obes Metab. 2021. PMID: 34463425 Free PMC article. Clinical Trial.
Upregulation of HLA class II in pancreatic beta cells from organ donors with type 1 diabetes.
Quesada-Masachs E, Zilberman S, Rajendran S, Chu T, McArdle S, Kiosses WB, Lee JM, Yesildag B, Benkahla MA, Pawlowska A, Graef M, Pfeiffer S, Mikulski Z, von Herrath M. Quesada-Masachs E, et al. Among authors: von herrath m. Diabetologia. 2022 Feb;65(2):387-401. doi: 10.1007/s00125-021-05619-9. Epub 2021 Dec 21. Diabetologia. 2022. PMID: 34932134
Progress in immune-based therapies for type 1 diabetes.
von Herrath M, Peakman M, Roep B. von Herrath M, et al. Clin Exp Immunol. 2013 May;172(2):186-202. doi: 10.1111/cei.12085. Clin Exp Immunol. 2013. PMID: 23574316 Free PMC article. Review.
336 results